Premium
P2‐431: RELATIONSHIP BETWEEN LOCAL RESTING STATE ACTIVITY, β‐AMYLOID DEPOSITION AND MEMORY PERFORMANCE IN THE DZNE: LONGITUDINAL COGNITIVE IMPAIRMENT AND DEMENTIA STUDY (DELCODE)
Author(s) -
Metzger Coraline D.,
Dyrba Martin,
Bittner Daniel,
Hu Xiaochen,
Jessen Frank,
Teipel Stefan J.,
Grothe Michael,
Oliver Peters,
Menne Felix,
Fuentes Manuel,
Priller Josef,
Spruth Eike,
Franke Christiana,
Schneider Anja,
Fließbach Klaus,
Kofler Barbara,
Wiltfang Jens,
Bartels Claudia,
Buerger Katharina,
Catak Cihan,
Kilimann Ingo,
Henf Judith,
Laske Christoph,
Buchmann Martina,
Spottke Annika,
Thelen Manuela,
Heneka Michael T.,
Brosseron Frederic,
Ramirez Alfredo,
Wagner Michael,
Wolfsgruber Steffen,
Roeske Sandra,
Frommann Ingo,
Polcher Alexandra,
Dobisch Laura,
Düzel Emrah
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1123
Subject(s) - dementia , audiology , pittsburgh compound b , cognition , default mode network , cognitive decline , resting state fmri , episodic memory , medicine , effects of sleep deprivation on cognitive performance , psychology , posterior cingulate , neuroscience , disease
(n1⁄411) had median CDR-SOB of 2. Age and sex matched controls (n1⁄426) were recruited. Area under the receiver-operating characteristic curve (AUROC) analysis was used to assess diagnostic accuracy of neurochemical measurements for distinguishing asymptomatic and symptomatic MAPT carriers from controls. Results:There was no significant difference in gender and education between groups, while asymptomatic group (35.3610.3 years) was significantly younger than symptomatic group (51.868.9 years, p1⁄40.0028) and healthy controls (49.6614.3 years, p1⁄40.0116). As expected, symptomatic group had significantly lower MoCA scores (19.8610.4) than asymptomatic group and healthy controls (p1⁄40.0338, p1⁄40.0415, respectively). The ratio of the neuronal metabolite N-acetylaspartate to glial metabolite myo-inositol (NAA/mI) from frontal lobe showed the best diagnostic accuracy in distinguishing symptomatic patients from controls (sensitivity 72.7%, specificity 92.3%, AUROC 0.836). The ratio of the glial metabolite myo-inositol to the reference metabolite creatine (mI/Cr) from the PCC showed the best diagnostic accuracy in distinguishing asymptomatic patients from controls (sensitivity 60.0%, specificity 61.54%, AUROC 0.623). However, the AUROC for each of the measurements was not different between PCC and frontal MRS voxels (p>0.05). Conclusions:MRS from frontal and PCC voxels had comparable diagnostic performance for distinguishing asymptomatic and symptomatic MAPT carriers from healthy controls. Neurochemical changes in the brain appear to bewide-spread involving both the PCC andmedial frontal lobes starting from the asymptomatic stages of the disease inMAPT mutation carriers.